To Be Discontinued Capsule Cardiovascular
Tafamidis Meglumine Capsule · 347 days since initial FDA posting
Brand: VYNDAQEL
FDA lists Tafamidis Meglumine Capsule as To Be Discontinued (Pfizer Inc.).
No availability text on this FDA row.
Tafamidis Meglumine Capsule: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Tafamidis Meglumine Capsule
- Manufacturer
- Pfizer Inc.
- Dosage Form
- Capsule
- Presentation
- Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-1975-40)
- Package NDC
- 0069-1975-40
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Sep 29, 2025
- Last Updated
- Sep 29, 2025
- Therapeutic Category
- Cardiovascular
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025.
FDA reason on file: Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025. General shortage guidance lives on the tracker hub.